Marketplace®
Every story is an economic story

Lexapro’s incredible tax-dodging journey

Reporter Jesse Drucker follows the sale of a bottle of anti-depressant Lexapro to see if it's worth it for a company to dodge taxes.

Download

Corporations will sometimes go to great lengths to avoid paying taxes. Is it worth it? Reporter Jesse Drucker explores this idea in a Bloomberg article following the money from the sale of a bottle of anti-depressant Lexapro.

The journey beings with a $99 bottle of Lexapro sold to someone in Phoenix, Ariz. Drucker found that $85 of the purchase ends up with New York City-based Forrest Laboratories, which makes the drug. But the majority of the profits then travel to Ireland, where Forrest makes the pills at a manufacturing facility that enjoys low taxes. The company then makes licensing payments to a subsidiary of itself in Bermuda, which has no corporate income tax, shifting a majority of the income out of Ireland into Bermuda.

Forrest earned nearly a billion dollars in pre-tax income in 2009, and spends in the low millions to save about $200 million on taxes.

Related Topics

Tagged as:

Latest Episodes

View All Shows
  • Marketplace
    9 hours ago
    25:45
  • Marketplace Morning Report
    16 hours ago
    7:02
  • Marketplace Tech
    21 hours ago
    7:01
  • This Is Uncomfortable
    5 days ago
    42:59
  • Million Bazillion
    14 days ago
    29:48
  • Make Me Smart
    5 months ago
    24:33